{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:19:56Z","timestamp":1784762396920,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40273-021-01091-w","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T06:44:25Z","timestamp":1633761865000},"page":"1343-1354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-3583","authenticated-orcid":false,"given":"Adnan","family":"Alsumali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence M","family":"Djatche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-1997","authenticated-orcid":false,"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-6089","authenticated-orcid":false,"given":"Rongzhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7151-4330","authenticated-orcid":false,"given":"Ibrahim","family":"Diakite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9793-7611","authenticated-orcid":false,"given":"Dipen","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3803-1817","authenticated-orcid":false,"given":"Dominik","family":"Lautsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"1091_CR1","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139\u2013e596."},{"issue":"6","key":"1091_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996\u20131004.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"1091_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.amjmed.2012.10.022","volume":"126","author":"JH Gurwitz","year":"2013","unstructured":"Gurwitz JH, Magid DJ, Smith DH, et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med. 2013;126(5):393\u2013400.","journal-title":"Am J Med"},{"issue":"2","key":"1091_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","volume":"6","author":"JE Ho","year":"2013","unstructured":"Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure. Circ Heart Fail. 2013;6(2):279\u201386.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"1091_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/ehf2.12455","volume":"6","author":"NE Ibrahim","year":"2019","unstructured":"Ibrahim NE, Song Y, Cannon CP, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry\u00ae. ESC Heart Fail. 2019;6(4):784\u201392.","journal-title":"ESC Heart Fail."},{"issue":"20","key":"1091_CR6","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1091_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","volume":"126","author":"BA Steinberg","year":"2012","unstructured":"Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction. Circulation. 2012;126(1):65\u201375.","journal-title":"Circulation"},{"issue":"1","key":"1091_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","volume":"11","author":"RS Vasan","year":"2018","unstructured":"Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of left ventricular systolic\u00a0dysfunction and heart failure in\u00a0the\u00a0Framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging. 2018;11(1):1\u201311.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1091_CR9","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","DOI":"10.1056\/NEJMoa1915928"},{"issue":"8","key":"1091_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jama.2014.6643","volume":"312","author":"J Butler","year":"2014","unstructured":"Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA. 2014;312(8):789\u201390.","journal-title":"JAMA"},{"issue":"9","key":"1091_CR11","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1007\/s12325-020-01456-1","volume":"37","author":"J Butler","year":"2020","unstructured":"Butler J, Djatche LM, Sawhney B, et al. Clinical and economic burden of chronic heart failure and reduced ejection fraction following a worsening heart failure event. Adv Ther. 2020;37(9):4015\u201332.","journal-title":"Adv Ther"},{"issue":"11 Supplement 1","key":"1091_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0735-1097(20)31436-4","volume":"75","author":"RJ Mentz","year":"2020","unstructured":"Mentz RJ, Djatche L, Pulungan Z, et al. Characteristics and outcomes of heart failure with reduced ejection fraction patients enrolled in Medicare Advantage with and without recent worsening heart failure. J Am Coll Cardiol. 2020;75(11 Supplement 1):809.","journal-title":"J Am Coll Cardiol"},{"key":"1091_CR13","doi-asserted-by":"crossref","unstructured":"DeVore AD, Hammill BG, Sharma PP, et al. In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. J Am Heart Assoc. 2014;3(4):e001088.","DOI":"10.1161\/JAHA.114.001088"},{"issue":"8","key":"1091_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","volume":"73","author":"J Butler","year":"2019","unstructured":"Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1091_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/phar.1701","volume":"36","author":"AP Bress","year":"2016","unstructured":"Bress AP, King JB, Brixner D, et al. Pharmacotherapy treatment patterns, outcomes, and health resource utilization among patients with heart failure with reduced ejection fraction at a US academic medical center. Pharmacotherapy. 2016;36(2):174\u201386.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1091_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ahj.2007.01.041","volume":"154","author":"S Setoguchi","year":"2007","unstructured":"Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260\u20136.","journal-title":"Am Heart J"},{"issue":"13","key":"1091_CR17","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482\u20137.","journal-title":"Circulation"},{"issue":"1","key":"1091_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/XCE.0000000000000190","volume":"9","author":"N Olchanski","year":"2020","unstructured":"Olchanski N, Vest AR, Cohen JT, et al. Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovasc Endocrinol Metab. 2020;9(1):17.","journal-title":"Cardiovasc Endocrinol Metab."},{"key":"1091_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2017.01.003","volume":"186","author":"JB Echouffo-Tcheugui","year":"2017","unstructured":"Echouffo-Tcheugui JB, Bishu KG, Fonarow GC, et al. Trends in health care expenditure among US adults with heart failure: the Medical Expenditure Panel Survey 2002\u20132011. Am Heart J. 2017;186:63\u201372.","journal-title":"Am Heart J"},{"issue":"3","key":"1091_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319.","journal-title":"Circ Heart Fail"},{"key":"1091_CR21","unstructured":"Institute for Clinical and Economic Review. ICER\u2019s reference case for economic evaluations: principles and rationale. 2020. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Reference_Case_013120.pdf. Accessed 4 Oct 2021."},{"issue":"10","key":"1091_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7326\/M16-0057","volume":"165","author":"AT Sandhu","year":"2016","unstructured":"Sandhu AT, Ollendorf DA, Chapman RH, et al. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med. 2016;165(10):681\u20139.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1091_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","volume":"104","author":"JJ McMurray","year":"2018","unstructured":"McMurray JJ, Trueman D, Hancock E, et al. Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104(12):1006\u201313.","journal-title":"Heart"},{"key":"1091_CR24","unstructured":"UK National Institute of Health and Care Excellence. Single technology appraisal. Sacubitril valsartan for treating heart failure with systolic dysfunction. Committee Papers. 2015."},{"key":"1091_CR25","unstructured":"US Centers for Disease Control and Prevention. National vital statistics reports. United States Life Tables, 2017. 2019."},{"key":"1091_CR26","unstructured":"US Centers for Disease Control and Prevention. National vital statistics reports. Deaths: Final Data for 2017. 2019."},{"key":"1091_CR27","doi-asserted-by":"crossref","unstructured":"McEwan P, Darlington O, McMurray JJ, et al. Cost\u2010effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health\u2010economic analysis of DAPA\u2010HF. Eur J Heart Fail. 2020;22(11):2147\u201356.","DOI":"10.1002\/ejhf.1978"},{"issue":"5","key":"1091_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","volume":"4","author":"JB King","year":"2016","unstructured":"King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392\u2013402.","journal-title":"JACC Heart Fail."},{"key":"1091_CR29","unstructured":"Bureau of Labor Statistics. Consumer Price Index. Medical care component 2021 [cited 2021 January 11]. Available from: https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=data"},{"key":"1091_CR30","unstructured":"PRINIVIL [prescribing information]. Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp. 2019."},{"key":"1091_CR31","unstructured":"COREG [prescribing information]. Research Triangle Park: GlaxoSmithKline. 2017."},{"key":"1091_CR32","unstructured":"ENTRESTO [prescribing information]. East Hanover: Novartis. 2019."},{"key":"1091_CR33","unstructured":"ALDACTONE [prescribing information]. New York: Pfizer Inc. 2008."},{"key":"1091_CR34","unstructured":"VERQUVO [prescribing information]. Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp. 2021."},{"key":"1091_CR35","unstructured":"IBM Micromedex. RED BOOK\u00ae 2021 [cited 2021 January 11]. Available from: http:\/\/micromedex.com"},{"issue":"1","key":"1091_CR36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/13696998.2021.1922195","volume":"24","author":"RJ Mentz","year":"2021","unstructured":"Mentz RJ, Pulungan Z, Kim S, et al. Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. J Med Econ. 2021;24(1):698\u2013705.","journal-title":"J Med Econ"},{"issue":"12","key":"1091_CR37","first-page":"1446","volume":"22","author":"EN Obi","year":"2016","unstructured":"Obi EN, Swindle JP, Turner SJ, et al. Health care costs for patients with heart failure escalate nearly 3-fold in final months of life. J Manag Care Spec Pharm. 2016;22(12):1446\u201356.","journal-title":"J Manag Care Spec Pharm"},{"key":"1091_CR38","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. OUP Oxford; 2006."},{"key":"1091_CR39","doi-asserted-by":"crossref","unstructured":"Gaziano TA, Fonarow GC, Velazquez EJ, et al. Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA Cardiol. 2020;5(11):1236\u201344.","DOI":"10.1001\/jamacardio.2020.2822"},{"issue":"6","key":"1091_CR40","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","volume":"1","author":"TA Gaziano","year":"2016","unstructured":"Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1(6):666\u201372.","journal-title":"JAMA Cardiol."},{"issue":"2","key":"1091_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","volume":"39","author":"GL Di Tanna","year":"2021","unstructured":"Di Tanna GL, Urbich M, Wirtz HS, et al. Health state utilities of patients with heart failure: a systematic literature review. Pharmacoeconomics. 2021;39(2):211\u201329.","journal-title":"Pharmacoeconomics"},{"key":"1091_CR42","doi-asserted-by":"crossref","unstructured":"Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014\u20132020). PharmacoEconomics. 2020;38(11):1219\u201336.","DOI":"10.1007\/s40273-020-00952-0"},{"issue":"11","key":"1091_CR43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, Rutten-van M\u00f6lken MP, Severens JL, et al. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408.","journal-title":"Pharmacoeconomics"},{"key":"1091_CR44","doi-asserted-by":"crossref","unstructured":"Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6(8):926\u201335.","DOI":"10.1001\/jamacardio.2021.1437"},{"issue":"11","key":"1091_CR45","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"21","key":"1091_CR46","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"5","key":"1091_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/phar.2108","volume":"38","author":"PM Zueger","year":"2018","unstructured":"Zueger PM, Kumar VM, Harrington RL, et al. Cost-effectiveness analysis of sacubitril\/valsartan for the treatment of heart failure with reduced ejection fraction in the United States. Pharmacotherapy. 2018;38(5):520\u201330.","journal-title":"Pharmacotherapy"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01091-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01091-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01091-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T16:50:25Z","timestamp":1699635025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01091-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01091-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"16 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The design and conduct of this study and manuscript development were funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rongzhe Liu, Ibrahim Diakite, and Dipen Patel are employees of OPEN Health, which received funding from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, to conduct the study. Adnan Alsumali, Laurence M. Djatche, Dominik Lautsch, and Yufei Wang were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may hold stock in Merck & Co., Inc., Kenilworth, NJ, USA. Andrew Briggs received compensation from Merck & Co., Inc., as a consultant for this work. He has also been contracted by Bayer, Eisai, Janssen, Novartis, Sword Health, Amgen, and Daichii Sankyo and received compensation outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The corresponding author has full access to all the data in the study. Data sharing is available upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The cost-effectiveness model was developed in Microsoft Excel 365 (Microsoft Corporation). Any additional information about model programming is available from the corresponding author upon request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This study relied on VICTORIA estimates and published literature as analysis inputs, therefore Ethics Committee approval was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients included in VICTORIA provided informed consent. This model did not involve human subjects.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients included in VICTORIA provided informed consent. This model did not involve human subjects","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}